argenx

The report covers idiopathic inflammatory myositis epidemiology, market trends, and emerging drugs in the US, EU4, UK, and Japan. Key highlights include 191,589 diagnosed cases in 2023, expected to rise by 2034, with the US having the highest cases (91,734). Marketed drugs like OCTAGAM 10% and VENOGLOBULIN-IH 5% IV, and emerging therapies such as Dazukibart and Efgartigimod are discussed. The market size was $447M in 2023, projected to grow due to emerging therapies.

The 'Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Forecast to 2034' report by ResearchAndMarkets.com provides an in-depth analysis of the market, epidemiology, and emerging therapies for idiopathic inflammatory myositis. Key highlights include the projected growth of the market driven by innovative therapies like dazukibart and efgartigimod, the rising prevalence of cases, and the market size of approximately USD 447 million in 2023, expected to grow at a CAGR of 21.1% by 2034. The report also covers current treatment practices, unmet medical needs, and market share by therapies in the 7MM (US, EU4, UK, Japan).

The FcRn inhibitor market report by ResearchAndMarkets.com provides insights into historical and competitive landscapes, market trends, emerging drugs, and forecasts from 2020 to 2034. Key players like Johnson & Johnson, UCB Biopharma, Pfizer, and Immunovant are developing FcRn inhibitors for autoimmune diseases. Prominent drugs include VYVGART, RYSTIGGO, and batoclimab, with positive trial results and FDA approvals. The market is expected to grow due to increasing diagnoses and emerging therapies.

Nuvig Therapeutics develops a first-in-class drug targeting type II Fc receptors to expand regulatory T cells, aiming to treat autoimmune diseases without chronic immunosuppression. The company secured $161 million for Phase 2 development of NVG-2089, tested for chronic inflammatory demyelinating polyneuropathy (CIDP). Unlike FcRn blockers, Nuvig's drug is immunomodulatory, potentially offering broader efficacy in CIDP.

DelveInsight's report highlights a robust lupus nephritis pipeline with 30+ companies developing 35+ therapies, including key players like AstraZeneca and Novartis. Promising therapies like Anifrolumab and Ianalumab are in various clinical phases, with recent updates from companies like Adicet Bio and Kyverna Therapeutics. The report provides comprehensive insights into the pipeline, therapeutic assessments, and market dynamics.

Argenx's subcutaneous efgartigimod alfa granted PIM status by UK MHRA for treating CIDP, signaling potential for EAMS inclusion. Designed to block autoimmune response, it aims to address unmet needs in CIDP treatment.

Halozyme withdrew offer to buy Evotec after refusal to engage; Neurogene's Rett syndrome gene therapy patient died from side effects; Argenx advances efgartigimod testing in myositis; Kyowa Kirin pays $330M upfront for Kura Oncology's leukemia drug; FDA's Douglas Throckmorton plans to retire.

The 'Lupus Nephritis - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of Lupus Nephritis treatments. It details the pipeline landscape, including disease overview, treatment guidelines, and assessments of emerging drugs like QLG1074, ADX-097, KYV-101, CABA-201, and NKX019. The report highlights ongoing R&D efforts, key collaborations, and trends in drug development, focusing on novel approaches to improve disease management. It also covers clinical trial stages, route of administration, and molecule types, identifying unmet needs and the impact of emerging therapies.

DelveInsight's report on Thrombocytopenia Market (2034) covers epidemiology, market trends in the US, EU4, UK, and Japan, highlighting the US as the largest market. Key companies include Sanofi, Principia Biopharma, Baxalta, Takeda, and others. Promising therapies such as VLX-1005, Herombopag, Avatrombopag Oral Tablet, Rilzabrutinib, and Nipocalimab are noted. Clinical trials by Qidong Gaitianli Medicines, Karyopharm Therapeutics, Janssen Research & Development, and Amgen are scheduled for June 2024. Marketed drugs like ADZYNMA (Takeda) and TAVALISSE (Rigel Pharmaceuticals/Kissei Pharmaceutical) are discussed. Emerging drugs like Rilzabrutinib (Sanofi/Principia Biopharma) are in Phase III for ITP treatment.

The global pharmacovigilance and drug safety software market is growing due to increased drug development spending and cloud-based solutions. The market, valued at $214.39 million in 2023, is expected to reach $359.30 million by 2031 with a CAGR of 6.7%. Key drivers include technological innovations like AI and machine learning, rising adverse drug reactions, and globalization of pharmacovigilance. North America leads the market, followed by Europe and Asia Pacific.